Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SupplySide West In Brief

This article was originally published in The Tan Sheet

Executive Summary

AREDS II rolling: Enrollment is complete and the second iteration of the National Eye Institute's Age-Related Eye Diseases Study is under way, according to Paul S. Bernstein, a researcher and professor of ophthalmology and visual sciences at the University of Utah School of Medicine's John A. Moran Eye Center. At the SupplySide West trade show in Las Vegas Oct. 22, Bernstein said through 2013, AREDS II will follow 4,000 patients between the ages of 50 and 85 with high risk for age-related macular degeneration at 100 U.S. sites. He explained that the antioxidant formulation for the first AREDS was "based on the best science of the 1980s" and omitted lutein and zeaxanthin, but the AREDS II formulation includes those carotenoids at levels about five times greater than a typical American diet. The revised formulation also lowers the original zinc and beta-carotene levels due to concerns about urinary tract problems and lung cancer, respectively. The AREDS results, released in 2001, showed high-dose antioxidant vitamins and minerals reduce the risk of advanced AMD progression by 25 percent (1"The Tan Sheet" Jan. 21, 2008, p. 14)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS102270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel